MA (EU) number	(Invented) name	Strength	Pharmaceutical Form	Route of Administration	Immediate Packaging	Content (concentration)	Pack size
EU/1/18/1272/001	Shingrix	--[1]	Powder and suspension for suspension for injection	Intramuscular use	powder: vial (glass) suspension: vial (glass)	Powder: 50 µg Suspension: 0.5 ml	1 vial (powder) + 1 vial (suspension)
EU/1/18/1272/002	Shingrix	--[1]	Powder and suspension for suspension for injection	Intramuscular use	powder: vial (glass) suspension: vial (glass)	Powder: 50 µg Suspension: 0.5 ml	10 vials (powder) + 10 vials (suspension)

--[1] After reconstitution, 1 dose (0.5 ml) contains 50 micrograms of gE antigen[1] adjuvanted with $AS01_B$[2].

[1] Varicella Zoster Virus (VZV) glycoprotein E (gE) produced by recombinant DNA technology in Chinese Hamster Ovarian (CHO) cells

[2] $AS01_B$ Adjuvant System is composed of the plant extract *Quillaja saponaria* Molina, fraction 21 (QS-21) (50 micrograms) and 3-O-desacyl-4'-monophosphoryl lipid A (MPL) from *Salmonella minnesota* (50 micrograms)